Literature DB >> 2482541

[Tumor necrosis factor (TNF) and pathology; its relationships with other cytokines].

G E Grau1, P H Lambert, P Vassalli, P F Piguet.   

Abstract

Tumor necrosis factor (TNF) is a cytokine produced mainly by activated monocytes/macrophages. We review here data obtained in four experimental models analyzed in our laboratory: cerebral malaria, graft-versus-host disease, BCG infection, and bleomycin-induced pulmonary fibrosis. We have shown that the triggering of these pathological conditions requires activation of T lymphocytes and overproduction of TNF, since these syndromes are associated with increased production of TNF mRNA and can be prevented either by T-cell depletion or by in vivo administration of neutralizing anti-TNF antibodies. These observations suggest that TNF is a central mediator in various immunopathological conditions and thus widen the field of T-cell mediated pathology.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2482541

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  5 in total

1.  Histological changes in small bowel mucosa induced by gliadin sensitive T lymphocytes can be blocked by anti-interferon gamma antibody.

Authors:  R T Przemioslo; K E Lundin; L M Sollid; J Nelufer; P J Ciclitira
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

2.  Prognostic value of anti-Plasmodium falciparum-specific immunoglobulin G3, cytokines, and their soluble receptors in West African patients with severe malaria.

Authors:  J L Sarthou; G Angel; G Aribot; C Rogier; A Dieye; A Toure Balde; B Diatta; P Seignot; C Roussilhon
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

3.  Sera from patients with falciparum malaria induce substance P gene expression in cultured human brain microvascular endothelial cells.

Authors:  C B Chiwakata; G Hort; C J Hemmer; M Dietrich
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

4.  Biological functionalization of drug delivery carriers to bypass size restrictions of receptor-mediated endocytosis independently from receptor targeting.

Authors:  Maria Ansar; Daniel Serrano; Iason Papademetriou; Tridib Kumar Bhowmick; Silvia Muro
Journal:  ACS Nano       Date:  2013-11-20       Impact factor: 15.881

5.  Tumor necrosis factor in benign and malign tissue of the kidney.

Authors:  K H Bichler; S Kleinknecht; H J Nelde; W L Strohmaier
Journal:  Urol Res       Date:  1991
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.